Bzam Ltd

Good morning, ladies and gentlemen. My name is Joelle and I will be your conference operator today. Welcome to BZAM LTD's fourth quarter full year 2022 conference call. To ensure an enjoyable experience for all participants, all lines have been placed on mute. Following the presentation, we will open the call for questions. If you would like to ask a question, simply press star then the number one. If you would like to withdraw your question, Press star, then two. This call is being recorded on Monday, May 1st, 2023. I would now like to turn the conference over to Matt Millich, Chief Executive Officer. Please go ahead.

Thank you, Joelle. Good morning, and thank you all for joining us for our Q1 2023 conference call. Joining me on the call this morning is Sean Bovingdon, our Chief Financial Officer. We had a busy start to the year and there's plenty to talk about, but first just wanted to note this call is being recorded and the audio recording will be available on the company website at bazaam.com. Also, today's discussion includes forward-looking statements. We caution that such statements are based on management's assumptions and beliefs and are subject to uncertainties and other factors that could cause actual results to differ materially. I refer you to our news release, and MD&A for more information on these assumptions and factors. With that, let's get started. 2023 is off to a strong start with Q1 delivering record quarterly gross revenues, increasing 41% quarter over quarter. This growth reflects the full impact of our November merger and the company's organic sales growth. We are very pleased with these results as they continue to prove out the investment thesis underpinning the merger. We have seen growth across nearly every product segment and have become the sixth largest producer in Canada. As we continue to execute on our plans to improve margin and reduce SG&A, we maintain a positive outlook on our march toward positive cash flow and EBITDA in the back half of this year. During the quarter, the company progressed the sales of the Poos Lynch and Maple Ridge facilities. Sales of these facilities are expected to be completed within the next 12 months. And following quarter end, we took steps to further streamline headcount. The impact of this will be discussed in the outlook section. We continue to leverage our industry-leading lab and innovation folks with the launch of over 20 new products across Canada in the next six months. And we continue to build momentum in the export market, having received our EU GMP certification earlier this month. This certification permits the company to export certain medicinal cannabis products to numerous global markets. We are executing on our distribution agreements in Germany and the UK, with branded products expected to land in the UK market by Q4 this year. We believe that we are well equipped to fulfill the international and domestic demand for our products in the year ahead. With that, I will now hand the call over to Sean to take you through the Q1 financial results. Following this, we will give a brief update on the outlook before taking questions.

Thank you, Matt, and good morning, everyone.